|
To learn more about Together with GSK Oncology, click here.
• ADVANCING Patient Support by ADC Therapeutics
• EAGLE CAN® (Care and Access Network)
• KaryForward®: Patient Support by Karyopharm Details >
• Changes to Claims Processing for Non-Physician Practitioners
• Infusion Pumps: Prevent Claim Denials
• Updated Medicare Hot Links Details >New training opportunities availableDetails >
Recent Oncology Related Articles• Physician Bonuses in Health Professional Shortage Areas
• HCPCS Application Summaries & Coding Decisions
• 2026 Medicare Advantage and Part D Advance Notice
• MLN Matters
• And More Details >• 2025 Specialty Measure Sets
• 2025 MIPS Resources
• Data Submission Open for 2024 Perf ormance Year Details >This edition includes articles on• 2025 Medicare Auditing: Key Changes & Trends
• How the Govt Could Push People Toward Medicare Advantage
• Coding Challenge: Understanding Underdosing
• Navigating Reclassification from Inpatient to Outpatient Observation Details >
Recent Oncology Related News• OncoHealth Manages Our Oncology Value Management Program
• Updated Medicare Advantage Coverage Policy
• 2025 Medicare Advantage, Part D Formulary Changes Details >Publications• The Record
• BCN Provider News Details >
Last Reviewed/Updated 1-21-25• Procrit or Epoetin Class Drugs Maintenance
• BCBSM Below Cost Reimbursement Details >Last Reviewed/Updated 1-21-25• 0885 Claims Denied With Reason Code 693
• Procrit or Epoetin Class Drugs Maintenance
• Procrit Denials (693)
• 505(b)(2) Oncology Products Being Impacted by Prior Auth Details >• New HAP 2025 Medicare Advantage Plans
• HAP CareSource Marketplace Plans Coming in 2025
• Benefit Policies, Prior Auth, & Pharmacy Info
• Multifactor Authentication Coming Soon Details >• Michigan’s Roadmap to Healthy Communities
• MI Selected by CMS to Participate in Behavioral Health Model Details >• Virtual Services Billing Updates
• January 30 Billing & Coding Webinar
• HMA Members Have Access to Priority Health’s Network
• New & Updated Billing Policies
• And More Details >• Medical Policy Updates
• Reimbursement Policy Updates
• Clinical Program Drug Step Therapy
• Care Provider Administrative Guide
• And More Details >
• Daiichi Sanyko & AstraZenca Datroway ® (datopotamab deruxtecan-dlnk)
• Amgen Lumakras® (sotorasib)
• AstraZeneca Calquence (acalabrutinib)
• Pfizer Braftovi® (encorafenib)
• BeiGene Tevimbra® (tislelizumab-jsgr)
• Bristol Myers Squibb Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Details > 
January 2025 Frequently Asked Questions• Reporting 96376 With 96374
• Coding for IVP Without Stop Time
• ISMP Documentation for Administering Higher-Risk Drugs
• REMS Eligibility For New Car-T Certified Centers
• And More Details > |
